GGrantIndex
← Leaderboards

Keith Thomas Gagnon

Southern Illinois University Carbondale

$5,999,933
Attributed
$5,999,933
Total exposure
10
Grants
10
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $1.3M · FY200925
$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$5,999,933 · 10

By mechanism

R61$1,785,797 · 1
R21$1,638,073 · 4
R01$1,115,733 · 1
R33$703,727 · 1
R15$442,500 · 1
R03$161,625 · 1

Top collaborators

No co-investigators on record.

Most similar at Southern Illinois University Carbondale

Same institution · by research overlap

Others in their field

Top investigators on “Cells

Research focus

CellsPharmaceutical PreparationsProteinsGeneticDesignNucleic AcidsBindingEnzymesIn VitroPropertyGenesMediatingGenetic TranscriptionGene ExpressionModificationChemistryMutantBaseGuide RnaProductionTranslationsAnimal ModelGenomeMethodology

Grant awards (22)

Coupling Epitranscriptomics to Molecular Disease Mechanisms and Nucleic Acid Therapeutics in Persistent Residual HIV Infection$703,727
R33 · FY2025 · AI · contact PI
Enabling Focused Ultrasound-Activated Gene Editing with Thermo-Controlled CRISPR-Cas9$421,811
R21 · FY2025 · GM · contact PI
Toward a Curative Treatment for HBV with cccDNA-Targeting Peptide Nucleic Acids$211,418
R21 · FY2025 · AI · contact PI
Coupling Epitranscriptomics to Molecular Disease Mechanisms and Nucleic Acid Therapeutics in Persistent Residual HIV Infection$534,319
R61 · FY2024 · AI · contact PI
Toward synthetic chemically defined mRNA for human therapeutics$230,891
R21 · FY2024 · GM · contact PI
Toward a Curative Treatment for HBV with cccDNA-Targeting Peptide Nucleic Acids$180,537
R21 · FY2024 · AI · contact PI
Coupling Epitranscriptomics to Molecular Disease Mechanisms and Nucleic Acid Therapeutics in Persistent Residual HIV Infection$348,314
R61 · FY2023 · AI · contact PI
Coupling Epitranscriptomics to Molecular Disease Mechanisms and Nucleic Acid Therapeutics in Persistent Residual HIV Infection$248,808
R61 · FY2023 · AI · contact PI
Nucleic Acid-Based Anti-CRISPR Inhibitors of Cas9$241,926
R01 · FY2023 · GM · contact PI
Toward synthetic chemically defined mRNA for human therapeutics$205,541
R21 · FY2023 · GM · contact PI
Nucleic Acid-Based Anti-CRISPR Inhibitors of Cas9$52,772
R01 · FY2023 · GM · contact PI
Coupling Epitranscriptomics to Molecular Disease Mechanisms and Nucleic Acid Therapeutics in Persistent Residual HIV Infection$654,356
R61 · FY2022 · AI · contact PI
Nucleic Acid-Based Anti-CRISPR Inhibitors of Cas9$269,720
R01 · FY2022 · GM · contact PI
Nucleic Acid-Based Anti-CRISPR Inhibitors of Cas9$269,720
R01 · FY2021 · GM · contact PI
Inhibiting C9ORF72 Repeat RNA Transcription with a Common Class of Small Molecules$387,875
R21 · FY2020 · NS · contact PI
Nucleic Acid-Based Anti-CRISPR Inhibitors of Cas9$281,595
R01 · FY2020 · GM · contact PI
Discovery of Small Molecules that Block Supt4h1-Supt5h Dimerization for Potential C9FTD/ALS Therapeutics$73,750
R03 · FY2020 · NS · contact PI
Nuclear Surveillance of Expanded Tandem Repeat RNA in C9FTD/ALS Disease$442,500
R15 · FY2019 · NS · contact PI
Discovery of Small Molecules that Block Supt4h1-Supt5h Dimerization for Potential C9FTD/ALS Therapeutics$87,875
R03 · FY2019 · NS · contact PI
Activating Gene Expression with Antigene RNAs to Treat Genetic Diseases$53,942
F32 · FY2012 · HD · contact PI
Activating Gene Expression with Antigene RNAs to Treat Genetic Diseases$51,326
F32 · FY2011 · HD · contact PI
Activating Gene Expression with Antigene RNAs to Treat Genetic Diseases$47,210
F32 · FY2009 · HD · contact PI